These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 11380444

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A.
    Chalmers EA, Brown SA, Keeling D, Liesner R, Richards M, Stirling D, Thomas A, Vidler V, Williams MD, Young D, Paediatric Working Party of UKHCDO.
    Haemophilia; 2007 Mar; 13(2):149-55. PubMed ID: 17286767
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis.
    Marcucci M, Mancuso ME, Santagostino E, Kenet G, Elalfy M, Holzhauer S, Bidlingmaier C, Escuriola Ettingshausen C, Iorio A, Nowak-Göttl U.
    Thromb Haemost; 2015 May; 113(5):958-67. PubMed ID: 25631402
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients.
    Gouw SC, Van Der Bom JG, Van Den Berg HM, Zewald RA, Ploos Van Amstel JK, Mauser-Bunschoten EP.
    Haemophilia; 2011 Mar; 17(2):275-81. PubMed ID: 21070499
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors.
    Luna-Záizar H, Beltrán-Miranda CP, Esparza-Flores MA, Soto-Padilla J, Bergés-García A, Rodríguez-Zepeda MD, Pompa-Garza MT, Jaloma-Cruz AR.
    Haemophilia; 2014 Jan; 20(1):e7-14. PubMed ID: 24354488
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Inhibitor development in previously untreated patients with severe haemophilia A: a nationwide multicentre study in Finland.
    Vepsäläinen K, Lassila R, Arola M, Huttunen P, Koskinen S, Ljung R, Lähteenmäki P, Möttönen M, Riikonen P.
    Haemophilia; 2016 Sep; 22(5):721-9. PubMed ID: 27339837
    [Abstract] [Full Text] [Related]

  • 15. Treatment related factors and inhibitor development in children with severe haemophilia A.
    Maclean PS, Richards M, Williams M, Collins P, Liesner R, Keeling DM, Yee T, Will AM, Young D, Chalmers EA, Paediatric Working Party of UKHCDO.
    Haemophilia; 2011 Mar; 17(2):282-7. PubMed ID: 21070501
    [Abstract] [Full Text] [Related]

  • 16. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study.
    Santagostino E, Mancuso ME, Rocino A, Mancuso G, Mazzucconi MG, Tagliaferri A, Messina M, Mannucci PM.
    Br J Haematol; 2005 Aug; 130(3):422-7. PubMed ID: 16042693
    [Abstract] [Full Text] [Related]

  • 17. Persistent factor VIII inhibitors and orthopaedic complications in children with severe haemophilia A.
    Abdel-Messih IY, Habashy DM, Moftah SG, ElAlfy MS.
    Haemophilia; 2011 May; 17(3):490-3. PubMed ID: 21371185
    [Abstract] [Full Text] [Related]

  • 18. Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients.
    Epstein J, Xiong Y, Woo P, Li-McLeod J, Spotts G.
    Haemophilia; 2012 Mar; 18(2):187-92. PubMed ID: 21883704
    [Abstract] [Full Text] [Related]

  • 19. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.
    Kreuz W, Escuriola Ettingshausen C, Vdovin V, Zozulya N, Plyushch O, Svirin P, Andreeva T, Bubanská E, Campos M, Benedik-Dolničar M, Jiménez-Yuste V, Kitanovski L, Klukowska A, Momot A, Osmulskaya N, Prieto M, Šalek SZ, Velasco F, Pavlova A, Oldenburg J, Knaub S, Jansen M, Belyanskaya L, Walter O, ObsITI study group, ObsITI committee.
    Haemophilia; 2016 Jan; 22(1):87-95. PubMed ID: 26202305
    [Abstract] [Full Text] [Related]

  • 20. Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study.
    Klukowska A, Komrska V, Jansen M, Laguna P.
    Haemophilia; 2011 May; 17(3):399-406. PubMed ID: 21118334
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.